His research interests include novel lipid-lowering therapies, antithrombotic therapies for atrial fibrillation and acute coronary syndromes (ACS), and the assessment of outcomes in patients with ACS. Dr Giugliano has authored more than 300 original articles and 200 reviews/editorials/book chapters. He is the Founding Scientific Advisor and Editor-in-Chief for MD Conference Express, Co-Editor-in-Chief of Cardiology and Therapy, and serves on editorial boards for Circulation, The American Heart Journal, Clinical Cardiology, Cor et Vasa, Hospital Practice, Cardiovascular Therapeutics and Clinical Pathways in Cardiology.

Dr Giugliano is the Principal TIMI Investigator for eleven clinical trials including the ENGAGE AF-TIMI 48 trial with edoxaban, and Executive Committee member of several additional trials including the IMPROVE-IT (ezetimibe) and FOURIER and VESALIUS-CV trials (evolocumab), and AZALEA-TIMI 71 (abelacimab) trials.